Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
- 7 November 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 381 (9860), 29-39
- https://doi.org/10.1016/s0140-6736(12)61855-8
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal ImpairmentDrug Safety, 2012
- Heart Disease and Stroke Statistics—2012 UpdateCirculation, 2012
- National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008JAMA, 2011
- Maternal vasodilation in pregnancy: the emerging role of relaxinAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureThe New England Journal of Medicine, 2011
- Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre‐RELAX‐AHF studyEuropean Journal of Heart Failure, 2010
- Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and SurvivalCirculation, 2010
- Relaxin: Review of Biology and Potential Role in Treating Heart FailureCurrent Heart Failure Reports, 2010
- Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β‐blockers in SURVIVE†European Journal of Heart Failure, 2009